This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-20 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
With the development of high-efficiency and high-power LEDs, it has become possible to use LEDs in lighting and illumination. To encourage the shift to LED lamps and other high-efficiency lighting, in 2008 the US Department of Energy created the L Prize competition. The Philips Lighting North America LED bulb won the first competition on August 3, 2011, after successfully completing 18 months of intensive field, lab, and product testing. Efficient lighting is needed for sustainable architecture. As of 2011, some LED bulbs provide up to 150 lm/W and even inexpensive low-end models typically exceed 50 lm/W, so that a 6-watt LED could achieve the same results as a standard 40-watt incandescent bulb. The lower heat output of LEDs also reduces demand on air conditioning systems. Worldwide, LEDs are rapidly adopted to displace less effective sources such as incandescent lamps and CFLs and reduce electrical energy consumption and its associated emissions. Solar powered LEDs are used as street lights and in architectural lighting. The mechanical robustness and long lifetime are used in automotive lighting on cars, motorcycles, and bicycle lights. LED street lights are employed on poles and in parking garages. In 2007, the Italian village of Torraca was the first place to convert its street lighting to LEDs. Cabin lighting on recent Airbus and Boeing jetliners uses LED lighting. LEDs are also being used in airport and heliport lighting.
Elongation factors are part of the mechanism that synthesizes new proteins through translation in the ribosome. Transfer RNAs (tRNAs) carry the individual amino acids that become integrated into a protein sequence, and have an anticodon for the specific amino acid that they are charged with. Messenger RNA (mRNA) carries the genetic information that encodes the primary structure of a protein, and contains codons that code for each amino acid. The ribosome creates the protein chain by following the mRNA code and integrating the amino acid of an aminoacyl-tRNA (also known as a charged tRNA) to the growing polypeptide chain. There are three sites on the ribosome for tRNA binding. These are the aminoacyl/acceptor site (abbreviated A), the peptidyl site (abbreviated P), and the exit site (abbreviated E). The P-site holds the tRNA connected to the polypeptide chain being synthesized, and the A-site is the binding site for a charged tRNA with an anticodon complementary to the mRNA codon associated with the site. After binding of a charged tRNA to the A-site, a peptide bond is formed between the growing polypeptide chain on the P-site tRNA and the amino acid of the A-site tRNA, and the entire polypeptide is transferred from the P-site tRNA to the A-site tRNA. Then, in a process catalyzed by the prokaryotic elongation factor EF-G (historically known as translocase), the coordinated translocation of the tRNAs and mRNA occurs, with the P-site tRNA moving to the E-site, where it dissociates from the ribosome, and the A-site tRNA moves to take its place in the P-site.
== Safety evaluations == AI safety evaluations (often referred to as "evals") are tests designed by researchers to evaluate the risk posed by a given artificial intelligence model. Evaluations can help determine both the risk posed by the raw model outputs, as well as the potential real-world outcomes of deploying such models. Running AI safety evaluations on frontier AI models before deployment is widely considered best practice, and governments have debated making some form of safety evaluation mandatory. Multiple AI companies, including Anthropic and OpenAI, have collaborated to run evaluations on each other's models before deployment. In September 2026, Anthropic CEO Dario Amodei called for the AI industry to slow the pace of development and announced that Anthropic would give independent evaluators permanent, employee-like access to its AI systems to verify the company's adherence to its safety practices. Some models have been found trying to cheat AI safety evaluations using strategies such as sandbagging (strategic under-performance on an eval in order to evade triggering concern), indicating "evaluation awareness", which can itself be measured by more sophisticated evaluations. AI safety evaluations can broadly be categorized as either testing the direct output of the model (model safety evaluations), or analyzing how access to the model can impact human behavior (contextual safety evaluations).
Sources: en.wikipedia.org
== External links == Quips article describing E3 Ligase function Archived 2012-11-30 at the Wayback Machine at PDBe Ubiquitin-Protein+Ligases at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 6.3.2.19
{\displaystyle {\begin{aligned}V=\left[H_{0}^{1}(\Omega )\right]^{d}&=\left\{\mathbf {v} \in \left[H^{1}(\Omega )\right]^{d}:\quad \mathbf {v} =\mathbf {0} {\text{ on }}\Gamma _{D}\right\},\\Q&=L^{2}(\Omega )\end{aligned}}}
Senegal: Foreign Minister Cheikh Niang held a phone call with Venezuelan Foreign Minister Yván Gil, expressing solidarity to the Venezuelan people and Senegal's commitment to international law, supporting the principle of non-intervention, and the right of Venezuelans to determine their own future. Somaliland: The Ministry of Foreign Affairs announced its support for the operation and stated that Somaliland believes that it can lead to a "peaceful, Venezuelan-led political transition". South Africa: The Department of International Relations released a press statement which viewed the US' actions "as a manifest violation of the Charter of the United Nations". The Charter "does not authorise external military intervention in matters that are essentially within the domestic jurisdiction of a sovereign nation", and South Africa pointed to history to demonstrate how "military invasions against sovereign states yield only instability and deepening crisis". It, furthermore, called on the United Nations Security Council (UNSC) to urgently convene to address the situation. Uganda: President Yoweri Museveni did not explicitly support or condemn the strikes, instead commenting on the military strategy during a youth forum on 4 January, stating he didn't know what they were fighting for but that he was "still studying it".
Sources: en.wikipedia.org
In 2009, the first to obtain FDA approval for topical DMSO usage was PENNSAID, which contains diclofenac in a carrier with 45.5% DMSO Each 1 mL of TDiclo contains 16.05 mg diclofenac sodium. TDiclo solution also contains 45.5% dimethyl sulfoxide (DMSO) vehicle, which can result in enhanced penetration of active drug through the skin. The most common adverse event reported was dry skin at the application site (25.3% of patients), followed by contact dermatitis (13.0%)In interventional radiology, DMSO is used as a solvent for ethylene vinyl alcohol in the Onyx liquid embolic agent, which is used in embolization, the therapeutic occlusion of blood vessels. In cryobiology DMSO has been used as a cryoprotectant and is still an important constituent of cryoprotectant vitrification mixtures used to preserve organs, tissues, and cell suspensions. Without it, up to 90% of frozen cells will become inactive. It is particularly important in the freezing and long-term storage of embryonic stem cells and hematopoietic stem cells, which are often frozen in a mixture of 10% DMSO, a freezing medium, and 30% fetal bovine serum. In the cryogenic freezing of heteroploid cell lines (MDCK, VERO, etc.) a mixture of 10% DMSO with 90% EMEM (70% EMEM + 30% fetal bovine serum + antibiotic mixture) is used. As part of an autologous bone marrow transplant the DMSO is re-infused along with the patient's own hematopoietic stem cells. DMSO is metabolized by disproportionation to dimethyl sulfide and dimethyl sulfone. It is subject to renal and pulmonary excretion.
The lactate racemase enzyme (Lar) (EC 5.1.2.1) interconverts the D- and L-enantiomers of lactic acid. It is classified under the isomerase, racemase, epimerase, and enzyme acting on hydroxyl acids and derivatives classes of enzymes. It is found in certain halophilic archaea, such as Haloarcula marismortui, and in a few species of bacteria, such as several Lactobacillus species (which produce D- and L-lactate) including Lactobacillus sakei, Lactobacillus curvatus, and Lactobacillus plantarum, as well as in non-lactic acid bacteria such as Clostridium beijerinckii. The gene encoding lactate racemase in L. plantarum was identified as larA and shown to be associated with a widespread maturation system involving larB, larC1, larC2, and larE. The optimal pH for its activity is 5.8-6.2 in L. sakei.
cell biology genetics cancer biology metabolism and obesity neuroscience and neurodegeneration infectious disease structural biology chemical biology chemistry In addition to faculty labs, the institute is home to research cores that provide services to the institute, the university, and external partners:
== Use as a biomarker == Dinosterol is used as a biomarker for organic matter derived from dinoflagellates in sediments and seawater. Biomarkers are organic compounds that are indicative of former life in sediments, seawater and oil. The presence of the saturated hydrocarbon counterpart, dinosterane, is used as evidence that some of the organic matter present in ancient sediments may have been derived from dinoflagellates.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.